The efficacy of recombinant fowlpox vaccine protection against Marek's disease: its dependence on chicken line and B haplotype.
Earlier studies have shown that the B haplotype has a significant influence on the protective efficacy of vaccines against Marek's disease (MD) and that the level of protection varies dependent on the serotype of MD virus (MDV) used in the vaccine. To determine if the protective glycoprotein gene gB is a basis for this association, we compared recombinant fowlpox virus (rFPV) containing a single gB gene from three serotypes of MDV. The rFPV were used to vaccinate 15.B congenic lines. Nonvaccinated chickens from all three haplotypes had 84%-97% MD after challenge. The rFPV containing gB1 provides better protection than rFPV containing gB2 or gB3 in all three B genotypes. Moreover, the gB proteins were critical, since the B*21/*21 chickens had better protection than chickens with B*13/*13 or B*5/*5 using rFPV with gB1, gB2, or gB3. A newly described combined rFPV/gB1gEgIUL32 + HVT vaccine was analyzed in chickens of lines 15 x 7 (B*2/*15) and N (B*21/*21) challenged with two vv+ strains of MDV. There were line differences in protection by the vaccines and line N had better protection with the rFPV/gB1gEgIUL32 + HVT vaccines (92%-100%) following either MDV challenge, but protection was significantly lower in 15 X 7 chickens (35%) when compared with the vaccine CVI988/Rispens (94%) and 301B1 + HVT (65%). Another experiment used four lines of chickens receiving the new rFPV + HVT vaccine or CVI988/Rispens and challenge with 648A MDV. The CVI 988/Rispens generally provided better protection in lines P and 15 X 7 and in one replicate with line TK. The combined rFPV/gB1gEgIUL32 + HVT vaccines protected line N chickens (90%) better than did CVI988/Rispens (73%). These data indicate that rFPV + HVT vaccines may provide protection against MD that is equivalent to or superior to CVI988/ Rispens in some chicken strains. It is not clear whether the rFPV/gB1gEgIUL32 + HVT vaccine will offer high levels of protection to commercial strains, but this vaccine, when used in line N chickens, may be a useful model to study interactions between vaccines and chicken genotypes and may thereby improve future MD vaccines.
Lee
Lucy F
LF
USDA, Agricultural Research Service, Avian Disease and Oncology Laboratory, 3606 East Mt. Hope Road, East Lansing, MI, USA.
Bacon
L D
LD
Yoshida
S
S
Yanagida
N
N
Zhang
H M
HM
Witter
R L
RL
D000818:Animals; D020296:Animals, Congenic; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology; D002645:Chickens / Q000235:genetics; D005587:Fowlpox virus / Q000235:genetics / Q000276:immunology*; D005814:Genes, Viral; D006239:Haplotypes; D026002:Herpesvirus 1, Meleagrid / Q000235:genetics / Q000276:immunology; D008381:Herpesvirus 2, Gallid / Q000235:genetics / Q000276:immunology; D025961:Herpesvirus 3, Gallid / Q000235:genetics / Q000276:immunology; D008380:Marek Disease / Q000276:immunology / Q000517:prevention & control*; D013045:Species Specificity; D014614:Vaccines, Synthetic / Q000235:genetics / Q000494:pharmacology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000235:genetics / Q000494:pharmacology*
D000956:Antigens, Viral; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C072811:glycoprotein B, Marek's disease virus